US Patent

US11807611 — Chlorinated tetralin compounds and pharmaceutical compositions

Method of Use · Assigned to SpringWorks Therapeutics Inc · Expires 2042-09-08 · 16y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects chlorinated tetralin compounds and pharmaceutical compositions.

USPTO Abstract

The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3754 — nirogacestat-hydrobromide
U-3754 — nirogacestat-hydrobromide
U-3754 — nirogacestat-hydrobromide

Patent Metadata

Patent number
US11807611
Jurisdiction
US
Classification
Method of Use
Expires
2042-09-08
Drug substance claim
No
Drug product claim
Yes
Assignee
SpringWorks Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.